OBJECTIVE: To assess the diagnostic performance of cell-free DNA assays in the detection of bladder cancer. PATIENTS AND METHODS: The quality of the studies included in this meta-analysis was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Statistical analyses were performed using the software RevMan 5.3 and Stata 14.0. We assessed the pooled sensitivity and specificity, positive/negative likelihood ratios (PLRs/NLRs), diagnostic odds ratios (DORs), and corresponding 95% confidence intervals (95% CIs). Summary receiver operating characteristic curve (ROC curve) and area under the curve (AUC) were used to summarize the overall test performance. Heterogeneity and publication bias were also examined. RESULTS: Eleven studies included 802 bladder cancer patients and 668 controls met the eligibility criteria. The overall diagnostic accuracy was measured as follows: sensitivity 0.71 (95% CI = 0.64-0.77), specificity 0.78 (95% CI = 0.70-0.85), PLR 3.3 (95% CI = 2.4-54.5), NLR 0.37 (95% CI = 0.30-0.46), DOR 9 (95% CI = 6-14), and AUC 0.80 (95% CI = 0.77-0.83). Subgroup analysis suggested that ethnicity significantly accounted for the heterogeneity of specificity. The Deeks' funnel plot asymmetry test (P = 0.97) suggested no potential publication bias. CONCLUSIONS: Cell-free DNA has a high diagnostic value in bladder cancer.
OBJECTIVE: To assess the diagnostic performance of cell-free DNA assays in the detection of bladder cancer. PATIENTS AND METHODS: The quality of the studies included in this meta-analysis was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Statistical analyses were performed using the software RevMan 5.3 and Stata 14.0. We assessed the pooled sensitivity and specificity, positive/negative likelihood ratios (PLRs/NLRs), diagnostic odds ratios (DORs), and corresponding 95% confidence intervals (95% CIs). Summary receiver operating characteristic curve (ROC curve) and area under the curve (AUC) were used to summarize the overall test performance. Heterogeneity and publication bias were also examined. RESULTS: Eleven studies included 802 bladder cancerpatients and 668 controls met the eligibility criteria. The overall diagnostic accuracy was measured as follows: sensitivity 0.71 (95% CI = 0.64-0.77), specificity 0.78 (95% CI = 0.70-0.85), PLR 3.3 (95% CI = 2.4-54.5), NLR 0.37 (95% CI = 0.30-0.46), DOR 9 (95% CI = 6-14), and AUC 0.80 (95% CI = 0.77-0.83). Subgroup analysis suggested that ethnicity significantly accounted for the heterogeneity of specificity. The Deeks' funnel plot asymmetry test (P = 0.97) suggested no potential publication bias. CONCLUSIONS: Cell-free DNA has a high diagnostic value in bladder cancer.
Authors: Annalisa Altimari; Antonia D'Errico Grigioni; Elisa Benedettini; Elena Gabusi; Riccardo Schiavina; Antonio Martinelli; Antonio Maria Morselli-Labate; Giuseppe Martorana; Walter Franco Grigioni; Michelangelo Fiorentino Journal: Am J Clin Pathol Date: 2008-05 Impact factor: 2.493
Authors: M T Valenzuela; R Galisteo; A Zuluaga; M Villalobos; M I Núñez; F J Oliver; J M Ruiz de Almodóvar Journal: Eur Urol Date: 2002-12 Impact factor: 20.096
Authors: Stefan Hauser; Monika Kogej; Guido Fechner; Alexander Von Ruecker; Patrick J Bastian; Jochen Von Pezold; Roland Vorreuther; Gerd Lümmen; Stefan C Müller; Jörg Ellinger Journal: Anticancer Res Date: 2012-08 Impact factor: 2.480
Authors: Antonin Brisuda; Eva Pazourkova; Viktor Soukup; Ales Horinek; Jan Hrbáček; Otakar Capoun; Iveta Svobodova; Sarka Pospisilova; Marie Korabecna; Jaroslav Mares; Tomáš Hanuš; Marek Babjuk Journal: Urol Int Date: 2015-09-03 Impact factor: 2.089